Gebauer Bernhard, Werk Michael, Lopez-Hänninen Enrique, Felix Roland, Althaus Peter
Department of Radiology, Charité, Universitätsmedizin Berlin Campus Virchow-Clinic, Augustenburger Platz 1, 13353, Berlin, Germany.
Cardiovasc Intervent Radiol. 2007 Jul-Aug;30(4):644-9. doi: 10.1007/s00270-007-9012-y.
To evaluate the feasibility and safety of minimally invasive, percutaneous techniques in metachronous recurrent renal cell cancers (RCCs) in solitary kidneys.
In 4 patients, recurrent RCC was treated by radiofrequency ablation (RFA) (RITA, StarBurst) alone, and in 2 patients by RFA in combination with superselective transarterial particle-lipiodol embolization using 3 Fr microcatheters. RFA was guided by computed tomography in 5 patients, and by magnetic resonance imaging in 1 patient. Mean tumor diameter was 26.7 mm (range 10-45 mm). All interventions were technically successful; during follow-up 1 patient developed recurrent RCC, which was retreated by RFA after embolization.
No major peri- or postprocedural complications occurred. Changes in creatinine (pre- vs. post-intervention, 122 vs. 127 micromol/l) and calculated creatinine clearance (pre- vs. post-intervention, 78 vs. 73 ml/min) after ablation were minimal.
In single kidneys, percutaneous, minimally invasive techniques are safe and feasible. In large tumors, or where there are adjacent critical structures, we prefer a combination of embolization and thermal ablation (RFA).
评估微创经皮技术治疗孤立肾中异时性复发性肾细胞癌(RCC)的可行性和安全性。
4例复发性RCC患者仅接受射频消融(RFA)(RITA,StarBurst)治疗,2例患者接受RFA联合使用3Fr微导管进行超选择性经动脉碘油颗粒栓塞治疗。5例患者的RFA由计算机断层扫描引导,1例由磁共振成像引导。平均肿瘤直径为26.7mm(范围10 - 45mm)。所有干预技术上均成功;随访期间1例患者出现复发性RCC,栓塞后再次接受RFA治疗。
未发生重大围手术期或术后并发症。消融后肌酐水平(干预前 vs. 干预后,122 vs. 127μmol/L)和计算的肌酐清除率(干预前 vs. 干预后,78 vs. 73ml/min)变化极小。
对于孤立肾,经皮微创技术安全可行。对于大肿瘤或存在相邻关键结构的情况,我们更倾向于栓塞和热消融(RFA)联合应用。